FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
May 29, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Priority Review recognises the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options1,2Additional analyses of INAVO120 will be presented in an...
FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
May 21, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone in the...
Novartis erzielt im ersten Quartal ein zweistelliges Umsatzwachstum und steigert die Kerngewinnmarge; Prognose für das Geschäftsjahr 2024 erhöht
April 23, 2024 01:00 ET
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KRDer Nettoumsatz wuchs im ersten Quartal um +11% (kWk1, +10% USD), das operative Kernergebnis verbesserte sich um +22% (kWk, +16% USD)Die wichtigsten...
Novartis, au premier trimestre: croissance à deux chiffres du chiffre d’affaires et expansion de la marge core; hausse des prévisions pour 2024
April 23, 2024 01:00 ET
|
Novartis Pharma AG
Annonce événementielle au sens de l’art. 53 RCRésultats du premier trimestre (T1)Chiffre d’affaires net en hausse de +11% (tcc1, +10% USD) et du résultat opérationnel core, de +22% (tcc, +16% USD) Les...
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
April 23, 2024 01:00 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LRQ1 net sales grew +11% (cc1, +10% USD) with core operating income up +22% (cc, +16% USD) Key growth drivers continued strong sales momentum including Entresto...
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
April 15, 2024 14:00 ET
|
Novartis Pharma AG
APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1IgAN is a heterogeneous, progressive, rare...
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
April 03, 2024 16:30 ET
|
Travere Therapeutics, Inc.
Travere Therapeutics to present abstracts at World Congress of Nephrology and American Nephrology Nurses Association on Rare Kidney Disease
Gabelli Funds to Host 10th Annual Waste & Environmental Services Symposium Thursday, April 4, 2024
April 01, 2024 15:16 ET
|
Gabelli Funds
GREENWICH, Conn., April 01, 2024 (GLOBE NEWSWIRE) -- Gabelli Funds, LLC, will host the 10th Annual Waste & Environmental Services Symposium at the Harvard Club in New York City on Thursday,...
UPDATE - Gabelli Funds to Host 10th Annual Waste & Sustainability Symposium Thursday, April 4, 2024
March 18, 2024 12:38 ET
|
Gabelli Funds
GREENWICH, Conn., March 18, 2024 (GLOBE NEWSWIRE) -- Gabelli Funds, LLC, will host the 10th Annual Waste & Sustainability Symposium at the Harvard Club in New York City on Thursday, April 4,...
Gabelli Funds to Host 10th Annual Waste & Sustainability Symposium Thursday, April 4, 2024
March 18, 2024 08:00 ET
|
Gabelli Funds
GREENWICH, Conn., March 18, 2024 (GLOBE NEWSWIRE) -- Gabelli Funds, LLC, will host the 10th Annual Waste & Sustainability Symposium at the Harvard Club in New York City on Thursday, April 4,...